Generic Menostar Availability

Menostar is a brand name of estradiol, approved by the FDA in the following formulation(s):

MENOSTAR (estradiol - film, extended release;transdermal)

  • Manufacturer: BAYER HLTHCARE
    Approval date: June 8, 2004
    Strength(s): 0.014MG/24HR [RLD]

Has a generic version of Menostar been approved?

No. There is currently no therapeutically equivalent version of Menostar available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Menostar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for treating postmenopausal women using ultra-low doses of estrogen
    Patent 5,891,868
    Issued: April 6, 1999
    Inventor(s): Cummings; Steven & Ellman; Herman & Ettinger; Bruce
    Assignee(s): Kaiser Foundation Health Plan, Inc. Permanente Medical Group, Inc. The Regents of the University of California Berlex Laboratories
    The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present invention.
    Patent expiration dates:
    • November 21, 2017
      ✓ 
      Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
      ✓ 
      Drug product
  • Methods for treating postmenopausal women using ultra-low doses of estrogen
    Patent 6,692,763
    Issued: February 17, 2004
    Inventor(s): Steven R.; Cummings & Bruce; Ettinger & Herman; Ellman
    Assignee(s): The Regents of the University of California Kaiser Foundation Health Plan, Inc. The Permanente Medical Group, Inc. Berlex Laboratories, Inc.
    The present invention provides methods for treating physical conditions resulting from postmenopausel estrogen decline in a postmenopausel subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit for carrying out the methods of the present invention.
    Patent expiration dates:
    • November 21, 2017
      ✓ 
      Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)